Having a commercial product capable of determining and delivering the trailer?s best aerodynamic profile based on real-time operating conditions may be a game-changer for the trucking industry, as fuel is a significant operating cost. This project will bring the pneumatic, sensor and artificial intelligence (AI) control systems from proof-of-concept to commercialization. The proposed device modifies the aerodynamic behavior of semi-trucks using air injection by allowing continuous optimization of aerodynamic performance. At highway speeds, aerodynamic drag uses over 65% of the total vehicle energy. Over 70% of US freight tonnage is moved by trucks. The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is reducing fuel consumption, improving safety and stability, and reducing the carbon footprint of the trucking industry while increasing profitability. Phase II work will mature shop optimization software through demonstration in a real aerospace parts factory. The solution demonstrates double digit improvements in all Key Performance Indicators (KPIs), such as on-time delivery (OTD), inventory turns, and profitability. The business model for delivering this software solution is designed for small and medium size businesses in terms of both cost and usability perspectives. The newly proposed methods, algorithms, and software may solve this challenge. Most scheduling optimizers are unable to handle this problem reliably or affordably. For shops with high product variety, low volume, large lead times, and large set up times, there is a need to find the optimal way to utilize existing resources in order to maximize production rate. This Small Business Innovation Research (SBIR) Phase II project involves the development of a new technology that enables high value manufacturers in optimizing the flow of materials in their shops. The technology may also help strengthen the national defense of the United States by facilitating onshoring of defense manufacturing by making domestic producers more cost competitive. The proposed technology may provide an affordable and easy-to-use solution for target markets in aerospace and medical technologies industries. The application addresses a need to find the optimal way of utilizing existing resources in order to maximize production rates. The broader impact of this Small Business Innovation Research (SBIR) Phase II project seeks to increase the competitiveness of the US in manufacturing high value parts for shops with high product variety, low volumes, large lead times, and large set up times. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. Effective editing will lead to disease correction in both patient cells and mice with no observable off-target editing events. The ErAcr protein will be paired with a novel CRISPR-Cas nuclease and developed into a therapy for SMA> The therapy will be packaged into an adeno-associated viral vector and tested for editing and SMA disease correction in patient-derived cells and in an SMA mouse model. This project will develop an engineered anti-CRISPR (ErAcr) protein to eliminate unintended off-target editing. High precision gene editing technology must be developed to ensure the safety and efficacy of in vivo gene editing therapies. This problem is particularly acute for in vivo therapies where the editing system will be delivered systemically or directly to the target organs, eliminating the ability to screen cells for unwanted editing outcomes. However, application of this technology has been limited by the high degree of unintended 'off-target' editing events. Manipulation of the human genome using CRISPR-Cas gene editors has been validated in early clinical trials to correct genetic diseases. This Small Business Innovation Research (SBIR) Phase II project will develop and validate a curative therapy for spinal muscular atrophy (SMA) using a novel and proprietary CRISPR-Cas precision gene editing system. This technology can be used to improve and even cure patients of genetic disease. The proposed technology will increase the safety and efficacy of gene editing by optimizing the precision of editing to correct the disease. The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be the development of a curative therapy for spinal muscular atrophy using a novel and proprietary precision gene editing technology.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |